Dublin, Feb. 21, 2025 (GLOBE NEWSWIRE) — The “Liquid Biopsy for Cancer Diagnostics Market Opportunities and Strategies to 2034” report has been added to ResearchAndMarkets.com’s offering.
The global liquid biopsy for cancer diagnostics market reached a value of nearly $9.22 billion in 2024, having grown at a compound annual growth rate (CAGR) of 15.72% since 2019. The market is expected to grow from $9.22 billion in 2024 to $19.81 billion in 2029 at a rate of 16.52%. The market is then expected to grow at a CAGR of 16.20% from 2029 and reach $41.97 billion in 2034.
The global liquid biopsy for cancer diagnostics market is fairly fragmented, with a large number of small players in the market. The top ten competitors in the market made up 24.44% of the total market in 2023. F. Hoffmann-La Roche AG was the largest competitor with a 4.95% share of the market, followed by Thermo Fisher Scientific Inc. with 3.17%, Guardant Health Inc. with 3.11%, Illumina Inc. with 2.87%, Exact Sciences Corporation with 2.20%, Natera Inc. with 2.07%, Johnson & Johnson Services Inc. with 1.93X%, Bio-Rad Laboratories Inc. with 1.90%, Caris Life Science with 1.19% and Sysmex Corporation with 1.06%.
Market-trend-based strategies for the liquid biopsy for cancer diagnostics market include focus on developing high-precision liquid biopsy for identifying cancer biomarkers, focus on revolutionizing next-generation automated liquid biopsy technologies for oncology and prenatal care, focus on developing next-generation liquid biopsy tools that improve cancer screening capabilities and focus on next-generation liquid biopsy tests to enhance personalized cancer treatment plans.
Player-adopted strategies in the liquid biopsy for cancer diagnostics market include focus on enhancing operational capabilities through strategic partnerships, focus on expanding business expertise through new launches focus on improving portfolio and strengthening its business through strategic acquisitions.
Growth in the historic period resulted from the rising demand for personalized medicine, rise in healthcare expenditure, increasing number of clinical trials and government initiatives for research and development in healthcare. Factors that negatively affected growth in the historic period was limited reimbursement policies. Going forward, the increasing cancer prevalence, growing aging population and growing cancer research investments will drive the growth. Factor that could hinder the growth of the liquid biopsy for cancer diagnostics market in the future include lack of trained personnel and high cost of technology.
The liquid biopsy for cancer diagnostics market is segmented by type into product and services. The product market was the largest segment of the liquid biopsy for cancer diagnostics market segmented by type, accounting for 72.93% or $6.72 billion of the total in 2024. Going forward, the services segment is expected to be the fastest growing segment in the liquid biopsy for cancer diagnostics market segmented by type, at a CAGR of 17.90% during 2024-2029.
The liquid biopsy for cancer diagnostics market is segmented by cancer into lung cancer, breast cancer, colon cancer and other cancers. The lung cancer market was the largest segment of the liquid biopsy for cancer diagnostics market segmented by cancer, accounting for 32.67% or $3.01 billion of the total in 2024. Going forward, the lung cancer segment is expected to be the fastest growing segment in the liquid biopsy for cancer diagnostics market segmented by cancer, at a CAGR of 18.99% during 2024-2029.
The liquid biopsy for cancer diagnostics market is segmented by sample into blood, urine and saliva. The blood market was the largest segment of the liquid biopsy for cancer diagnostics market segmented by sample, accounting for 79.82% or $7.36 billion of the total in 2024. Going forward, the urine segment is expected to be the fastest growing segment in the liquid biopsy for cancer diagnostics market segmented by sample, at a CAGR of 18.84% during 2024-2029.
The liquid biopsy for cancer diagnostics market is segmented by end user into hospitals, diagnostic centers and other end users. The hospitals market was the largest segment of the liquid biopsy for cancer diagnostics market segmented by end user, accounting for 55.83% or $5.15 billion of the total in 2024. Going forward, the diagnostic centers segment is expected to be the fastest growing segment in the liquid biopsy for cancer diagnostics market segmented by end user, at a CAGR of 19.95% during 2024-2029.
North America was the largest region in the liquid biopsy for cancer diagnostics market, accounting for 47.21% or $4.35 billion of the total in 2024. It was followed by Western Europe, Asia Pacific and then the other regions. Going forward, the fastest-growing regions in the liquid biopsy for cancer diagnostics market will be Asia Pacific and Western Europe where growth will be at CAGRs of 18.06% and 17.14% respectively. These will be followed by North America and South America where the markets are expected to grow at CAGRs of 16.37% and 14.04% respectively.
To take advantage of the opportunities, the analyst recommends the liquid biopsy for cancer diagnostics companies to focus on developing high-precision liquid biopsy solutions, focus on advancing automated liquid biopsy technologies, focus on advancing next-generation tools for enhanced cancer screening, focus on advancing next-generation liquid biopsy solutions, focus on enhancing tumor detection and profiling in liquid biopsy, expand in emerging markets, focus on expanding distribution channels for liquid biopsy solutions, focus on developing competitive and accessible pricing strategies, focus on building awareness through targeted educational campaigns, focus on strengthening digital and social media marketing and focus on targeting hospitals and diagnostic centers for enhanced market penetration.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 262 |
| Forecast Period | 2024 – 2034 |
| Estimated Market Value (USD) in 2024 | $9.22 Billion |
| Forecasted Market Value (USD) by 2034 | $41.97 Billion |
| Compound Annual Growth Rate | 16.4% |
| Regions Covered | Global |
Top Opportunities
- The top opportunities in the liquid biopsy for cancer diagnostics market segmented by type will arise in the product segment, which will gain $7.39 billion of global annual sales by 2029.
- The top opportunities in the liquid biopsy for cancer diagnostics market segmented by cancer will arise in the lung cancer segment, which will gain $4.17 billion of global annual sales by 2029.
- The top opportunities in the liquid biopsy for cancer diagnostics market segmented by end user will arise in the hospitals segment, which will gain $5.16 billion of global annual sales by 2029.
- The top opportunities in the liquid biopsy for cancer diagnostics market segmented by sample will arise in the blood segment, which will gain $8.22 billion of global annual sales by 2029.
- The liquid biopsy for cancer diagnostics market size will gain the most in the USA at $4.28 billion.
Major Market Trends
- High-Precision Liquid Biopsy for Identifying Cancer Biomarkers
- Advancements in Automated Liquid Biopsy Technologies for Oncology and Prenatal Care
- Next-Generation Liquid Biopsy Tool Improves Cancer Screening Capabilities
- Technological Advancement in Liquid Biopsy for Personalized Cancer Treatment
- Enhancing Tumor Detection and Profiling With Liquid Biopsy
Key Mergers and Acquisitions
- Quest Diagnostics Acquired Haystack Oncology
- Exact Sciences Corporation Acquired Resolution Bioscience, Inc.
- Exact Sciences Corporation Acquired Thrive Earlier Detection
Markets Covered:
- Type: Product; Services
- Cancer: Lung Cancer; Breast Cancer; Colon Cancer; Other Cancers
- Sample: Blood; Urine; Saliva
- End User: Hospitals; Diagnostic Centers; Other End Users
Some of the major companies featured in this Liquid Biopsy for Cancer Diagnostics market report include:
- F. Hoffmann-La Roche AG
- Thermo Fisher Scientific Inc.
- Guardant Health Inc.
- Illumina Inc.
- Exact Sciences Corporation
- Natera Inc.
- Johnson & Johnson Services Inc.
- Bio-Rad Laboratories Inc.
- Caris Life Science
- Sysmex Corporation
- Strand Life Sciences
- Adicon Holdings Limited
- SOPHiA GENETICS SA
- QIAGEN N. V.
- Novigenix
- Roche Diagnostics Polska Sp. z o.o.
- Janssen Diagnostics LLC
- Twist Bioscience
- Biocept
- BioMark Diagnostics Inc.
- GRAIL, Inc.
- Foundation Medicine, Inc.
- GeneCentric Therapeutics Inc.
- DGLAB
- Oncoclinicas Group
- Grupo Fleury
- Detectiome
- Anwa Medical Company
- Syndicate Bio
- PathCare
- Axaitech
For more information about this report visit https://www.researchandmarkets.com/r/wbicz2
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Liquid Biopsy for Cancer Diagnostics Market
